Cellular Biomedicine Group Expands and Strengthens Leadership Team
May 27 2015 - 8:00AM
Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the
"Company"), a biomedicine firm engaged in the development of
effective stem cell therapies for degenerative diseases and
immunotherapies for cancer, today announced the appointment of
Richard L. Wang, Ph.D., MBA, PMP as Chief Operating Officer. The
announcement comes at an appropriate time as CBMG continues to
build its cell therapy platforms and expands its operational
facilities.
"We are very pleased to welcome Dr. Wang, a seasoned and
accomplished industry professional to the Company's management
team," said Dr. William (Wei) Cao, Chief Executive Officer for the
Company. "He brings tremendous operational, project management, and
R&D governance experience from multinational pharmaceutical
companies, as well as a scientific background that will support the
research of osteoarthritis, oncology and neuroscience therapeutics.
His addition reflects our ability to attract successful executives
based on the progress and growth potential of our Stem Cell and
Immuno-Oncology platforms. Dr. Wang will play a critical role in
the management of research collaborations, technology transfers,
drug development clinical trials, regulatory affairs, production,
and oversight of our multicenter operations. Dr. Wang's end-to-end
knowledge and experience in the pharmaceutical R&D, strategy
and operational execution both in China and the U.S. will prove to
be a strong asset to the Company."
"As society increasingly recognizes the importance of
immunotherapies and stem cell therapies to treat many unmet medical
conditions, CBMG's cellular therapy platforms are very unique and
compelling," said Dr. Wang. "I am excited about the opportunity to
join CBMG to help lead the company through its next phase of
execution in operational excellence, and to work with the
leadership team to reach the Company's full potential of globally
improving the quality of life for millions of people."
About Dr. Richard L. Wang
Dr. Wang is a seasoned leader, manager and scientist in
pharmaceutical R&D organizations, with experience covering drug
discovery, platform technology, project leadership, project and
portfolio management, R&D governance, strategic alliance,
business development, academic collaboration, research outsourcing,
R&D operations, organizational development, compliance, and
site and facility management.
Dr. Wang received his B.S. degree in Cell Biology from the
University of Science & Technology of China, his Ph.D. in
Molecular Biology from the University of Maryland, Baltimore and
his MBA from Xavier University in Cincinnati. In addition to his
strong academic background, he has over twenty-one years of
professional leadership experience in several multinational
companies such as Procter & Gamble, Bristol-Myers Squibb,
AstraZeneca and GlaxoSmithKline both in the U.S. and China.
His most recent position was Senior Site Leader and Head of
Operations, GSK R&D in Shanghai, China.
Dr. Wang is a frequent invited speaker and panelist for many
international scientific and pharmaceutical R&D and business
forums in China and Asia, and a Lecturer of Drug Discovery and
Development courses at the University of Science & Technology
of China and Shanghai Jiaotong University.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell
therapies for the treatment of certain degenerative diseases and
cancers. Our developmental stem cell, progenitor cell, and immune
cell projects are the result of research and development by
scientists and doctors from China and the United
States. Our flagship GMP facility in China, consisting of eight
independent cell production lines, is designed, certified and
managed according to U.S. standards. To learn more about CBMG,
please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities or investments, and other statements
that are not descriptions of historical facts may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include, but are not
limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as
"may," "will," "expects," "plans," "intends," "estimates,"
"potential," or "continue," or similar terms or the negative of
these terms. Although CBMG believes the expectations reflected in
the forward-looking statements are reasonable, they cannot
guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to
update these forward-looking statements other than as required by
law.
CONTACT: Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566-5064
sarah.kelly@cellbiomedgroup.com
Vivian Chen
Managing Director Investor Relations, Grayling
+1 347 481-3711
vivian.chen@grayling.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024